VGLL1 and gastric cancer: Clinical studies have shown that higher tumor VGLL1 expression correlates with lower overall survival in pancreatic cancer, gastric cancer, basal-like breast cancer, and breast cancers that become resistant to SERD therapy (4, 8, 9, 11, 24).